Share Name Share Symbol Market Type Share ISIN Share Description
Yourgene Health Plc LSE:YGEN London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 6.75 67,000 07:46:15
Bid Price Offer Price High Price Low Price Open Price
6.50 7.00 6.75 6.75 6.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 18.29 -12.01 -1.80 49
Last Trade Time Trade Type Trade Size Trade Price Currency
08:11:43 O 27,000 6.50 GBX

Yourgene Health (YGEN) Latest News

More Yourgene Health News
Yourgene Health Investors    Yourgene Health Takeover Rumours

Yourgene Health (YGEN) Discussions and Chat

Yourgene Health Forums and Chat

Date Time Title Posts
20/5/202007:42YourGene to Infinity2,121
04/5/202008:06Partnership with Novacyt 2
30/3/202008:20Yourgene Health at the UK Investor Show3

Add a New Thread

Yourgene Health (YGEN) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2022-06-28 15:13:556.505,385350.03O
2022-06-28 14:39:516.60100,0006,600.00O
2022-06-28 12:57:186.7260,0004,033.20O
View all Yourgene Health trades in real-time

Yourgene Health (YGEN) Top Chat Posts

Yourgene Health Daily Update: Yourgene Health Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker YGEN. The last closing price for Yourgene Health was 6.75p.
Yourgene Health Plc has a 4 week average price of 6.75p and a 12 week average price of 6.75p.
The 1 year high share price is 17.25p while the 1 year low share price is currently 6.75p.
There are currently 727,100,243 shares in issue and the average daily traded volume is 290,180 shares. The market capitalisation of Yourgene Health Plc is £49,079,266.40.
hjb1: Interesting post from GLT on the other bb. Sure he won't mind (Long post) I truly enjoyed the CMD presentation and discussions thereof - a rare occasion, since Covid, to meet, listen to and discuss with management & leadership team on the business status, progress and plans. As I mentioned yesterday, I had the privilege to sit next to Dr Bill Chang and asked if he has sold - he said no - and yes, one can withhold the truth but not Dr Bill Chang. He is major shareholder, director and even though shares in a different vehicle it is a declarable event. So, people, please stop making things up. I wrote before re Genmark Diagnostics, loss-making but with IP & repeatable sales company, being bought for $1.8bn at 9x sales by Roche. It is reassuring to see John's presentation highlighting the same, at 10x sales or 40x EBITDA. Companies are flush with cash and need to deploy them. Why 9-10x sales? Well, these companies have very high GP%, say 60% - this makes the multiple versus GP closer to 15x (they don't need the overheads) which if in a growth category, will quickly reduce again. Most of the large co's are on multiples higher than 15x, so it is market value enhancing. I think we have to almost "write off" the 2 Covid yrs, like most companies in our space. It created an abnormal down / upturn in results in a non-continuing event. We have capitalised on revenue & its contribution to scale up and expand our offerings, geographic presence and structure / infrastructure. We should now focus on the core - and let's be very clear - YGEN is not a Covid business. Many of those have taken a hit, like we have, but in time the market will realise we are not a Covid business! Back to the core. We have a great NIPT test but I have always thought the difference in quality (we are better) isn't going to allow the land grab. To change and adopt new, there has to be clear business cases for existing labs, and new labs are enticed by the big players with their own tests. BUT in Ranger, and in the same way we improved our NIPT test / workflow - working 2-3 years with Ranger / Coastal Genomics on it , YGEN have spotted a significant USP that not only opens up a new market (the DNA enrichment) in the workflow but also the door towards YGEN end-to-end solution. This will be the game changer for us. Add to that, the ability for us to improve existing diagnostic tests within our own genomic services. I wrote as a Q - why would an existing / new lab adopt this ie value proposition - well, they answered it: cost savings, improvement in tests ie patient and clinical benefits and ability to do more with less. A no-brainer almost! Something we did not have before. And we are not only NIPT. Not much is spoken about the other tests we provide but also the services in doing the test in our labs. DPYD is a winner, and there is a portfolio of over 300 tests. Add to that, the strategic agreement with Ambry Genetics. Speaking of which, OMG, the market reaction to the announcement has been a big surprise. Speaking to YGEN folks in the room, they were equally disappointed. It's a big deal. Not just us providing our tech, but the ability for us to access theirs. Ambry has a large portfolio of oncology tests - this will be a growth driver for our genomic services division. I don't know, but I imagine it is a revenue sharing model or royalty type arrangement. When I look at a business, and forgive me for repeating, I assess: - the category/sector they are in: trends, growth potential, players etc; - the product/services they offer: USP / differentiation; - business model: how they make money; - management team: can they execute; - traction / momentum: validation, key customers, distribution model etc - funding needs: more dilution or not, constraints etc Well, having understood the business even more from yesterday, YGEN SHOULD go places, and the management believes so too. And from a pretty heartfelt Lynn, I think he is equally disappointed with share price performance but I am confident it will take care of itself in time. That's if one of the big players don't swallow us up. Time to buy. Good luck all. PS: I understand the institutional investors were also highly receptive of the session yesterday. Will they add? Will they advise their clients to add? I don't know but I am pretty sure they will have felt a lot more convinced after yesterday. They move slow ie lots of steps before making the investment. You and I don't have that "red tape". Capitalise on that.
phatomtraider: It is always the same every 6 months. LR gives a good presentation. All the LTHs fall over themselves gushing. Some even buy further to leverage down. Some things remain constant. No sight of Break-Even/Profit, Revenue down this year, Founders are leaving and selling shares, no strategy for shareholder return for LTHs. The 1 Covid Company that didn't have a Covid spike! Fact remains when LR took over the share price was 16p and the size of shares in circulation was a 1/5th of what they are now. With AR potentially selling now, we may see the share price crash to 7p again. Certainty is that the Options gravy train will accelerate as past Options exercise price is now at too much of a premium to current share price And so, LR will need to double their Options to retain the staff. Just get the Company sold, and go and work for one of your mates whose Company you bought at an inflated premium LOL.
sapporo59: GLTader Price: 9.25 Strong Buy RE: RNS X 2!Today 20:26 Loved every bit of the presentation. Understand so much more about the company, its offering, differentiation/USP and route to market. Hang tight as share price is not reflective of its value, I strongly believe. Will write more in due course. One thing to clarify. I had the privilege to sit next to Dr Bill Chang. Said hello and contrary to whoever that posted, he hasn't offloaded a single share and don't intend to until....... TruroTrader Price: 9.25 No Opinion RE: RNS X 2!Today 19:49 I was basically encouraged. A lot of info re two of the main products. State side is already into one of the super labs and working on another re NIPT. The Ex5 takeover is paying real service dividends compared to what we paid for it. If the share price does not rise to much this week I will top-up. Natdan Price: 9.25 No Opinion RE: RNS X 2!Today 19:06 Didn’t listen in its entirety as lost the will with the tech explanations. What struck me most was the chap who flew in from the US, busily outlining how many takeovers and mergers the sector has undergone and, as far as I could ascertain, as good as putting out an open invitation to any out there to come and buy us, preferably at a substantial premium of course. Ygen seems to have so many products it is difficult to see decent market penetration any time soon in any specific area. The Ranger tech is portrayed as the jewel in the crown which might eventually tempt one of the bigger players to swallow us as a morsel. In the meantime, the Waiting for Godot scenario remains the order of the day. Stas20 Price: 9.25 No Opinion RE: RNS X 2!Today 18:11 oops hxxps:// Stas20 Price: 9.25 No Opinion RE: RNS X 2!Today 18:11 This is the presentation talked to, yes there will be a recording and the Q&A will be answered. Stas20 Price: 9.25 No Opinion RE: RNS X 2!Today 18:09 Wow how is it that we have so few people here and these meetme's happen maybe twice a year and are then are missed. priorities guys, you've known for weeks. Most important point for me, even though LR acknowledged that questioned had come through whilst online - they were not addressed, we are told they will be in the writeup. Only two questions even asked and one answered by the question, jeez!! Mostly presentations of case studies, Ok they weren't boring however Dr Rachel Shelmerdine lacked intonation, was slightly monotone and actually sounded like she should be in bed with an inhalation. Lots of presenting about the products, Ranger actually look very good. We are selling now in the US and may have large advantage in our advanced process over other current testing, a good example given was in providing the blood for testing EDTA tubes i.e. when taking blood our system only need one tube taken and that gives enough for 5 tests, other systems need labs to take two vials of blood as they need the lot for only one test, so they take two vials in case one is spoiled. Takes the cost of providing the sample from around $8 to $20 that's at the test providers expense, so its in financial interest for the people to use the cheapest system more profit for them. Thus our technology, pretty much across the board are both our own IP AND the most advanced AND potentially the cheapest for the customer win, win, win. Lots shown including marketing film etc around ranger tech, looks good. Actually if I wasn't already a shareholder, there was enough there to make me want to do a bit more digging. But to be honest as presenters go, Scott was good, Bhavika was good, Rachel needs some rest! Potential to take advantage of our IP. Big Markets, Big opportunity. Latin America could also be exciting. too much to take in, not really a presentation for me, better for a team of medical decision makers, oncologists, hospitals etc. I just want to know when my shares are going to be worth at least what I paid for them so I can reassess whether to hold or fold.!!!!
catch007: APAD: My YGEN holding is small in comparison to your own held in my growth portfolio the vast majority of my shares held in my income portfolio Sincerely hope the share price rises for you. Time for LR & co to step up to the plate if they agree share price undervalued and increase their skin in the game.
catch007: I am hopeful that on Tuesday we will get a progressive update from YGEN. The run rate for testing I suspect remains very strong and testing volumes will be driving revenue growth. I note several Covid testing stocks AVCT, ODX etc have been marked down heavily in recent months and Covid sentiment may well have also impacted YGEN share price though it is not a one trick pony with a strong NIPT business. Looking for some positive framework news as it has been a 4 lot damp squib to date and also confirmation of US partners will be helpful. Unfortunately we may see further delays in global business growth with further Covid restrictions being imposed. Hoping that we may see recovery from the 12p range on the back of results. GLA
ngen yap: Our share price performance is truly frustrating.Why PIs are selling now is truly baffling. Perhaps people are just tired of waiting and fed up.But....YGEN now have a siginificant Covid business, both in test kits and lab services, supplying both private commercial organisations and the government. Whatever we think in terms of how long Covid testing will last, it will be a minimum of 6-12 months. Thereafter, we are told the facilities can be repurposed for other genomic activities - I hope management will tell us what they are next Tuesday.YGEN have a growing NIPT, reproductive health, DYPD etc ie non-Covid business. The expansion into USA has only just begun and the market size there is probably the size of the international market. So, big growth potential - again, hope we will hear more details on Tuesday.So, whilst I am equally frustrated with share price, will hold until business fundamentals tell me otherwise.In the meantime, please management, you can help the share price and sentiments. Let's start with next Tuesday.
catch007: I note myhealthchecked is launching two Covid tests. YGEN I trust will be the processing Lab? Given the rise in infection rates in Europe YGEN must be processing large volumes of tests currently given the run rate highlighted in AGM presentation. Seems baffling then that the share price is anchored around 12p. Some news is needed soon to move the the share price north again as revenues must be strong.
catch007: Never had the Friday feeling with YGEN share price uplift you describe I will stick to crunchie bars!
phatomtraider: It is funny when rampers who post ad nauseum find a contrarian single post enough qualification to consider a person a troll, or enough to shake their views in a Company. If you believe in the Company, BoD, CEO and product and strategy then sod what anyone says on a BB. You must be pretty unconvinced on your investment if a single post has shaken your confidence. Who are you trying to convince. On the aside it is equally funny when aliases are taken, but the posting style does not @-; I don't believe that even YGEN's leaking ship of an Investment Team had revealed who had sold the Options, but then BB readers can work it out for themselves. You just have to go through the Options Award RNS history and see who has been awarded Options at 10.25 pence. Rampers have been suggesting that the Results will reveal a boom. Could be. However the point that I was making was that the exercise of Options on the 17th June (when the share price was @ circa 13.25p) indicated a pessimistic attitude within the Company. If you think that the BoD, each year, have been awarding themselves a few millions worth of Options then you would have hoped that that they would have been incentivised to make the share price appreciate more than they have. If they do not care of the sp, and just want to get on with the day job, then stop awarding yourselves Options at pace. Exercising Options @10.25p when the share price is @13.25p is hardly a vote of confidence. Trawl through the Options RNS and you get to the 03rd June 2019 RNS. Where you can see who were awarded Options @10.25p. Lyn Rees: 4,000,000 Barry Hextall: 400,000 Bill Chang: 400,000 Hayden Jeffreys: 2,400,000 So if it was not Barry Hextall, then who else would you prefer it to be? The current CEO? Remember the 17th June 2021 gave notice of two exercise of options of 400,000 new ordinary shares in the Company at an exercise price of 10 pence per share and over 150,000 new ordinary shares in the Company at an exercise price of 10.25 pence per share, as above, by two employees. So when you look at who got Options @10p you can only find Dr Stephen Little 10,555,984 options at that exercise price on 2 October 2014 RNS. Would you prefer then the past CEO? SP weakness has been dire and persistent since the beginning of the year (Feb RNS) when the 1st warning signs were given , with no good news able to shift trajectory downwards as if something is known. Lots of good posters tried to give warnings, only to be replaced by paid rampers and aliases. Not much time to go now. If I was a betting man, I would say that with AR's track record another acquisitive placing is coming up, as it has been some time since the Coastal Genomics purchase. On that note the share price weakness could be indicating a 2nd element of the Earn Out Fee for Coastal Genomics that saw 14,945,689 added to the shares in circulation. My reading is that LR has paid too much for these acquisitions which are not resulting in revenue expectations he promised to shareholders, hence some II's dumping in the face of share drag and year-on-year "jam-tomorrow" expectations. At some point CEO's need to deliver value to their shareholders, and LR's largess seems to be more at the expense of existing PIs and LTHs. Just call it a day and sell the freaking Company, and put your shareholders out of their year-on-year misery.
phatomtraider: Are you still getting amused? If BMD is getting his contract wins correct, that means someone is leaking it to him. So you are then talking of someone at Director level who has inside knowledge of the Contract Pipeline. Why would a Director leak this to BMD and others? To aid them as a tipster? Provide PIs an inside track before the IIs? Realistically it was to facilitate a pump and dump. PIs alone do not account for a 20%+ fall in the share price despite successive RNS, on potential transformational contracts. And I do not think the Seller is expecting a quick bounce from TU, otherwise just release the TU and get over it, quick sharp. PI's should be angry here, but not against singular contrary posts against the rampfest to facilitate a pump and dump to facilitate a better price for the Seller. LR has failed to add share price value here despite the years and Options given. Whether it be organic growth, price paid for acquisitions, expensive earn out fees, false-start of IONA Nx roll-out and the lost opportunity of the last year where the wrong strategy was clearly chosen. With sub-13p expected by next week, PIs should really be asking when LR will actually deliver share price value for them having taken over when the share price was 16.5p.
Yourgene Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Yourgene H..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220629 11:11:47